Form 4: Keros Therapeutics Director Julius Knowles Equity Grant

Director Julius Knowles received a grant of 7,142 restricted stock units and 7,433 stock options from Keros Therapeutics.

Summary

• Director Julius Knowles was granted 7,142 restricted stock units (RSUs) on June 3, 2026.
• The RSUs are scheduled to vest on the earlier of June 3, 2027, or the date of the 2027 annual stockholders meeting.
• A stock option grant for 7,433 shares was also issued with an exercise price of $10.50.
• The stock options vest in equal quarterly installments over 12 months, fully vesting by the 2027 annual meeting.
• Following these transactions, the director holds 13,583 shares directly, with additional indirect holdings through investment funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedules ensure continued service commitment from the director.

Negatives

• Issuance of equity awards results in minor dilution to existing shareholders.

Risks

• Vesting is contingent upon the director continuing to provide service to the company.
• Market price volatility could impact the future value of the granted options.

Future Outlook

The equity grants are subject to continued service through the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap biotechnology firms.
• Vesting periods of 12 months for options are relatively standard for annual director refresh grants.

Related Party Transactions

• The reporting person is a partner of Partners GP I and Partners GP II, which manage funds holding Keros Therapeutics stock.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs on June 3, 2027 or the 2027 annual meeting date.
• Quarterly vesting of stock options over the next 12 months.

Key Dates

Keywords

Keros Therapeutics, KROS, Form 4, Insider Trading, Equity Compensation, Director Compensation